Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 10 2019
Historique:
received: 11 12 2018
revised: 29 04 2019
accepted: 11 07 2019
pubmed: 20 7 2019
medline: 22 9 2020
entrez: 20 7 2019
Statut: ppublish

Résumé

Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappearance of HBV (prior HBV, hereafter) has yet to be determined. This study aimed to detect integration of HBV and adeno-associated virus type 2 (AAV2) into the human genome as a possible oncogenic event. Virome capture sequencing was performed, using HCC and liver samples obtained from 243 patients, including 73 with prior HBV without hepatitis C viral (HCV) infection and 81 with chronic HBV. Clonal HBV integration events were identified in 11 (15.0%) cases of prior HBV without HCV and 61 (75.3%) cases of chronic HBV ( Despite the seroclearance of hepatitis B surface antigen, HBV or AAV2 integration in prior HBV was not rare; therefore, such patients are at risk of developing HCC.

Identifiants

pubmed: 31320595
pii: 1078-0432.CCR-18-4041
doi: 10.1158/1078-0432.CCR-18-4041
doi:

Substances chimiques

Antibodies, Viral 0
DNA, Viral 0
Hepatitis B Surface Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6217-6227

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Kenji Tatsuno (K)

Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.

Yutaka Midorikawa (Y)

Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan. mido-tky@umin.ac.jp haburata-tky@umin.ac.jp.
Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.

Tadatoshi Takayama (T)

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan.

Shogo Yamamoto (S)

Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.

Genta Nagae (G)

Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan.

Mitsuhiko Moriyama (M)

Department of Gastroenterology and Hepatology, Nihon University School of Medicine, Tokyo, Japan.

Hayato Nakagawa (H)

Department of Gastroenterology, University of Tokyo, Tokyo, Japan.

Kazuhiko Koike (K)

Department of Gastroenterology, University of Tokyo, Tokyo, Japan.

Kyoji Moriya (K)

Department of Infectious Diseases, University of Tokyo, Tokyo, Japan.

Hiroyuki Aburatani (H)

Genome Science Division, RCAST, University of Tokyo, Tokyo, Japan. mido-tky@umin.ac.jp haburata-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH